Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk

Stephen J Greene^{1

2}, Gregg C Fonarow³, Javed Butler⁴

Affiliations

¹ Duke Clinical Research Institute, Durham, NC (S.J.G.).
² Division of Cardiology, Duke University School of Medicine, Durham, NC (S.J.G.).
³ Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.).
⁴ Department of Medicine, University of Mississippi Medical Center, Jackson (J.B.).

Stephen J Greene et al. Circ Heart Fail. 2020 Jun.

. 2020 Jun;13(6):e007132.

doi: 10.1161/CIRCHEARTFAILURE.120.007132. Epub 2020 Jun 2.

Stephen J Greene^{1

2}, Gregg C Fonarow³, Javed Butler⁴

¹ Duke Clinical Research Institute, Durham, NC (S.J.G.).
² Division of Cardiology, Duke University School of Medicine, Durham, NC (S.J.G.).
³ Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.).
⁴ Department of Medicine, University of Mississippi Medical Center, Jackson (J.B.).

No abstract available

Keywords: clinical trial; heart failure; risk; therapeutics.

MeSH terms